Anixa Biosciences is trading 5.12% down at $2.78, with no clear catalyst established.
- On October 1, 2026, the company said a second patient had been treated in the highest-dose cohort of its ovarian cancer CAR-T trial.
- It reported no dose-limiting toxicities to date and four patients surviving more than one year. The announcement did not attribute any stock move to the update; broader market conditions also do not clearly explain the decline.